MiR-155 and JMJD1A in Nasopharyngeal Carcinoma
Author Information
Author(s): Du Zi-Ming, Hu Li-Fu, Wang Hai-Yun, Yan Li-Xu, Zeng Yi-Xin, Shao Jian-Yong, Ernberg Ingemar
Primary Institution: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China
Hypothesis
The study aims to assess the expression pattern of miR-155 in nasopharyngeal carcinoma (NPC) and its potential targets.
Conclusion
MiR-155 is upregulated in NPC, partly driven by LMP1 and LMP2A, and downregulates JMJD1A, which is associated with poor prognosis.
Supporting Evidence
- MiR-155 was found to be upregulated in NPC clinical samples.
- Downregulation of JMJD1A was significantly correlated with N stage in TNM classification.
- Lower five-year survival rates were associated with low JMJD1A expression.
Takeaway
This study found that a tiny molecule called miR-155 is more active in a type of throat cancer, and it can turn down a gene that helps predict how well patients will do.
Methodology
The study used quantitative Real-time PCR, in situ hybridization, and luciferase reporter assays to analyze miR-155 expression and its targets.
Limitations
The study is retrospective and relies on archived tissue samples, which may not represent current clinical practices.
Participant Demographics
185 NPC patients (144 males and 41 females; aged from 16 to 73 years; median age 47 years)
Statistical Information
P-Value
p=0.021 for overall survival related to JMJD1A expression
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website